Omnicin Therapeutics

Omnicin Therapeutics is developing Bismocin, a first-in-class inhaled therapy designed to restore antibiotic effectiveness against Pseudomonas aeruginosa (PA) lung infections in patients with chronic respiratory diseases such as cystic fibrosis (CF), non-CF bronchiectasis, and COPD. These patients are particularly vulnerable to antimicrobial resistance (AMR), and existing treatments are losing efficacy as resistance and biofilms develop, leading to progressive lung decline and repeated hospitalizations.

Bismocin repurposes the well-known compound bismuth subcitrate into a novel inhaled dry powder. By disrupting PA’s iron metabolism, it collapses bacterial resistance mechanisms and re-sensitizes pathogens to standard antibiotics, effectively turning failing treatments back into successful therapies without altering clinical practice. The proprietary, patentable formulation will be delivered through the Cyclops inhalation device, for which Omnicin holds an option for an exclusive license already validated in the target patient population.

The therapy’s mechanism has been published in Nature Microbiology, and preclinical data demonstrate strong synergy with antibiotics, eradication of resistant PA in animal models, and favorable safety. With regulatory alignment on a streamlined preclinical pathway, Omnicin is preparing for its first clinical studies. Led by a team of experienced biotech entrepreneurs and microbiology experts, Omnicin Therapeutics aims to deliver a transformative solution for resistant lung infections, offering both life-changing patient benefits and strong potential for market impact.